New chickenpox vaccine trial aims to protect 300 kids
NCT ID NCT07473427
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new chickenpox vaccine in 300 healthy children aged 1 to 12 years. All children will receive one dose of the vaccine. Researchers will check if the vaccine triggers a strong immune response and is safe to use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jun 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 year to 12 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Healthy children aged 1-12 years; 2. Vaccination history: * Participants aged 1 year old: no vaccination history with any varicella containing vaccine; * Participants aged 2\~12 years old: no vaccination history with any varicella containing vaccine, or have received 1 dose of varicella vaccine at least 3 months before enrollment; 3. Participants and/or their legal guardians are able to understand and sign the informed consent/assent voluntarily; 4. Participants are able to comply with the study procedures based on the assessment of the investigator; 5. Participants should provide verifiable identification, to be contacted, and to contact the investigator during the study period. Exclusion Criteria: 1. Prior history of VZV infection; 2. Have been exposed to VZV at home, day care, school, etc. within 4 weeks before enrollment; 3. Known allergy to vaccines or vaccine ingredients, or serious adverse reactions to vaccines, such as urticaria, dyspnea, angioneurotic edema; 4. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, ankylosing spondylitis, autoimmune thyroid diseases, asplenia, functional asplenia, and HIV infection); 5. Coagulation disorders (e.g. factor deficiency, platelet disorders), or history of bleeding, hematoma, or bruising following intramuscular injections or venipuncture; 6. Poorly controlled chronic illnesses or history of severe diseases that, including but not limited to cardiovascular diseases, hematological disorders, liver and kidney diseases, digestive system disorders, respiratory diseases, malignancies, and a history of major organ transplantation; 7. Any confirmed or suspected syphilis, hepatitis B or hepatitis C infection; 8. Current or history of severe neurological diseases (epilepsy, convulsions or seizures \[excluding history of febrile seizures\]) or psychiatric disorders, or presence of a family history of psychiatric disorders; 9. Receipt of ≥14 days of immunosuppressive or other immunomodulatory therapy (prednisone ≥20mg/day, or prednisone ≥2mg/kg/day, or its equivalent), cytotoxic therapy within 180 days prior to screening, or plans for such treatment during the trial; 10. Receipt of blood products or immunoglobulins within 180 days prior to screening, or plans to receive these treatments in the trial; 11. Receipt of other investigational drugs/vaccines within 30 days prior to screening, or plans to receive such drugs or vaccines during the study period; 12. Receipt of attenuated live vaccines or nucleic acid vaccines within 28 days prior to screening, or subunit or inactivated vaccines within 7 days prior to screening; 13. Fever on vaccination day, with axillary temperature \>37.2°C pre-vaccination, or vital signs outside normal range, or failure to pass physical examination; 14. Presence of skin injuries, inflammation, ulcers, rashes, scars, or other conditions at the intended injection site that may interfere with drug administration or observation of local reactions; 15. Acute onset of various acute diseases or chronic diseases within the past 7 days, or known or suspected active infections; 16. Any other factors considered by the investigator to make the participant unsuitable for participation in the trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Varicella (chickenpox) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Hanoi Medical University
Hanoi, 100000, Vietnam
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Four-in-One vaccine match the gold standard for childhood protection?
- New chickenpox vaccine shows promise in large Kids' trial
- Booster shot for chickenpox: study seeks stronger protection for kids
- Could a new vaccine beat chickenpox? large trial underway
- New pneumonia vaccine shows promise in toddlers and infants